$27 Mln
$-10 Mln
--
As on 22-Sep-2023 16:00 EDT
$0.01
•
4.95%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Vaccinex (VCNX)
| -75.81 | -31.53 | -59.66 | -76.55 | -69.53 | -54.77 | -- |
|
S&P BSE Sensex
| 8.49 | 1.22 | 3.91 | 11.02 | 20.17 | 12.37 | 12.54 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|
|
Vaccinex (VCNX)
| -38.46 | -49.76 | -57.32 | 33.07 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Vaccinex Inc. (VCNX) stood at $ 7 Mln as on 31-Mar-23
The share price of Vaccinex Inc. (VCNX) is $0.154800 (NASDAQ) as of 22-Sep-2023 16:00 EDT. Vaccinex Inc. (VCNX) has given a return of -69.53% in the last 3 years.
Vaccinex Inc. (VCNX) has a market capitalisation of $ 27 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of Vaccinex Inc. (VCNX) is 5.53 times as on 02-Jun-2023, a 1.18% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Vaccinex Inc. (VCNX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vaccinex Inc. (VCNX) and enter the required number of quantities and click on buy to purchase the shares of Vaccinex Inc. (VCNX).
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.
The CEO & director of Dr. Maurice Zauderer Ph.D.. is Vaccinex Inc. (VCNX), and CFO & Sr. VP is Mr. Scott E. Royer C.F.A., M.B.A..
The promoters of Vaccinex Inc. (VCNX) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
523
|
|
|
498
|
|
|
497
|
|
|
392
|
| Vaccinex Inc. (VCNX) | Ratios |
|---|---|
|
Return on equity(%)
|
-459.92
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0.03
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Vaccinex Inc. (VCNX) was $-10 Mln.
$27.38 Mln
$0.65 Mln
$-10.14 Mln
$3.32 Mln
$0.43 Mln
High
$0.13 - 0.82
65,286,000
NASDAQ: VCNX
Rochester, NY
https://www.vaccinex.com
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a... humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
